MX2012004624A - Metodos para tratar canceres positivos para el receptor de androgenos. - Google Patents
Metodos para tratar canceres positivos para el receptor de androgenos.Info
- Publication number
- MX2012004624A MX2012004624A MX2012004624A MX2012004624A MX2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A
- Authority
- MX
- Mexico
- Prior art keywords
- androgen receptor
- receptor positive
- positive cancers
- treating androgen
- positive cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 102000001307 androgen receptors Human genes 0.000 title abstract 4
- 108010080146 androgen receptors Proteins 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se proporciona un método para inhibir la multiplicación de células cancerosas positivas para el receptor de andrógenos. El método implica administrar a un individuo con diagnóstico o sospecha de tener un cáncer positivo para el receptor de andrógenos una composición que contiene un compuesto que puede inhibir el crecimiento del cáncer positivo para el receptor de andrógenos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25439509P | 2009-10-23 | 2009-10-23 | |
PCT/US2010/053916 WO2011050353A1 (en) | 2009-10-23 | 2010-10-25 | Method for treating androgen receptor positive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012004624A true MX2012004624A (es) | 2012-08-23 |
Family
ID=43900720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012004624A MX2012004624A (es) | 2009-10-23 | 2010-10-25 | Metodos para tratar canceres positivos para el receptor de androgenos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US8835447B2 (es) |
EP (1) | EP2490531A4 (es) |
JP (1) | JP2013508417A (es) |
KR (1) | KR20120095402A (es) |
CN (1) | CN102573472A (es) |
AP (1) | AP2012006277A0 (es) |
AU (1) | AU2010310477A1 (es) |
BR (1) | BR112012009262A2 (es) |
CA (1) | CA2779309A1 (es) |
EA (1) | EA201290208A1 (es) |
GE (1) | GEP20146138B (es) |
IL (1) | IL219331A0 (es) |
MX (1) | MX2012004624A (es) |
WO (1) | WO2011050353A1 (es) |
ZA (1) | ZA201202557B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG186076A1 (en) | 2010-05-28 | 2013-01-30 | Univ Texas | Oligo-benzamide compounds and their use |
WO2013023300A1 (en) * | 2011-08-15 | 2013-02-21 | The University Of British Columbia | Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use |
US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
US8835493B2 (en) | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
JP6138928B2 (ja) | 2012-06-01 | 2017-05-31 | ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー.ファウ.(エフエルイー) | 医薬に使用されるnotchシグナル伝達経路及び分泌の阻害物質 |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
ES2818915T3 (es) * | 2012-07-13 | 2021-04-14 | Oncternal Therapeutics Inc | Método para tratar cánceres de mama con un modulador selectivo del receptor de andrógenos (SARM) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
NZ704487A (en) * | 2012-07-27 | 2018-05-25 | Aragon Pharmaceuticals Inc | Methods and compositions for determining resistance to androgen receptor therapy |
WO2014153043A1 (en) * | 2013-03-14 | 2014-09-25 | Health Research, Inc. | Compounds and methods for treating cancers |
WO2015042297A1 (en) * | 2013-09-20 | 2015-03-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compounds for treating prostate can cancer |
US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
WO2018015958A1 (en) * | 2016-07-21 | 2018-01-25 | Hadasit Medical Research Services And Development Ltd. | Ar antagonists or inhibitors for use in treating glioblastoma |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224326A (en) * | 1978-09-21 | 1980-09-23 | Eli Lilly And Company | Immunosuppressive agents |
AU626881B2 (en) | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
WO1996014090A1 (en) * | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
KR20060130781A (ko) * | 2004-04-08 | 2006-12-19 | 토포타겟 에이/에스 | 다이페닐 인돌-2-온 화합물 및 암 치료에 있어서의 그의용도 |
AU2005257982B8 (en) * | 2004-06-16 | 2011-03-10 | Jack Arbiser | Carbazole formulations for the treatment of psoriasis and angiogenesis |
GB0513702D0 (en) * | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
JP2009528383A (ja) * | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害剤として用いるためのチアゾロン |
US20100130579A1 (en) * | 2006-10-23 | 2010-05-27 | Georgetown University | Cancer therapy |
-
2010
- 2010-10-25 CA CA2779309A patent/CA2779309A1/en not_active Abandoned
- 2010-10-25 MX MX2012004624A patent/MX2012004624A/es not_active Application Discontinuation
- 2010-10-25 AU AU2010310477A patent/AU2010310477A1/en not_active Abandoned
- 2010-10-25 AP AP2012006277A patent/AP2012006277A0/xx unknown
- 2010-10-25 CN CN2010800474879A patent/CN102573472A/zh active Pending
- 2010-10-25 EA EA201290208A patent/EA201290208A1/ru unknown
- 2010-10-25 GE GEAP201012711A patent/GEP20146138B/en unknown
- 2010-10-25 KR KR1020127013113A patent/KR20120095402A/ko not_active Application Discontinuation
- 2010-10-25 US US13/501,566 patent/US8835447B2/en not_active Expired - Fee Related
- 2010-10-25 JP JP2012535441A patent/JP2013508417A/ja active Pending
- 2010-10-25 BR BR112012009262A patent/BR112012009262A2/pt not_active IP Right Cessation
- 2010-10-25 EP EP10825802.1A patent/EP2490531A4/en not_active Withdrawn
- 2010-10-25 WO PCT/US2010/053916 patent/WO2011050353A1/en active Application Filing
-
2012
- 2012-04-10 ZA ZA2012/02557A patent/ZA201202557B/en unknown
- 2012-04-22 IL IL219331A patent/IL219331A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011050353A8 (en) | 2011-07-14 |
KR20120095402A (ko) | 2012-08-28 |
AU2010310477A1 (en) | 2012-05-03 |
US20120264771A1 (en) | 2012-10-18 |
EA201290208A1 (ru) | 2012-10-30 |
CA2779309A1 (en) | 2011-04-28 |
JP2013508417A (ja) | 2013-03-07 |
AP2012006277A0 (en) | 2012-06-30 |
WO2011050353A1 (en) | 2011-04-28 |
IL219331A0 (en) | 2012-06-28 |
EP2490531A1 (en) | 2012-08-29 |
CN102573472A (zh) | 2012-07-11 |
GEP20146138B (en) | 2014-08-11 |
BR112012009262A2 (pt) | 2019-09-24 |
US8835447B2 (en) | 2014-09-16 |
EP2490531A4 (en) | 2013-06-19 |
ZA201202557B (en) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012004624A (es) | Metodos para tratar canceres positivos para el receptor de androgenos. | |
MY160399A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
TN2015000140A1 (en) | Modulation of androgen receptor expression | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
MX348566B (es) | Tratamiento del cáncer con inhibidores de tor cinasa. | |
MX346635B (es) | Derivados citotoxicos de la benzodiazepina. | |
MX341151B (es) | Composiciones para reducir la metanogenesis gastrointestinal en rumiantes. | |
MX354217B (es) | Composiciones y metodos para el tratamiento de leucemia. | |
GB201306736D0 (en) | Releasable corrosion inhibitors | |
NZ596488A (en) | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
MX2012010226A (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
MX2010009765A (es) | Moleculas pequeñas que contienen boro como agentes anti-inflamatorios. | |
WO2010056378A3 (en) | Extracellular matrix compositions for the treatment of cancer | |
MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
NZ601584A (en) | Methods for treating colorectal cancer | |
NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
MX2012001562A (es) | Tratamiento de astrocitos-celulas de tumor con inhibidores de receptores de endotelina. | |
GEP201706612B (en) | Methods for the treatment of breast cancer | |
AU2010306870A8 (en) | Reducing the risk of pathological effects of traumatic brain injury | |
MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
WO2010099489A3 (en) | Ovarian cancer methylome | |
EP2606909A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT, PREVENTION AND DIAGNOSIS OF CANCER WITH CANCER STEM CELLS OR CELLS OBTAINED THEREFROM | |
MX2012012744A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
WO2012071562A3 (en) | Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |